Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

66.70
-0.9800-1.45%
Post-market: 66.41-0.2900-0.43%19:30 EDT
Volume:1.59M
Turnover:106.77M
Market Cap:12.89B
PE:176.00
High:68.34
Open:67.55
Low:66.52
Close:67.68
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:0.90
T/O Rate:0.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:2.04
PE(LYR):37.06

Loading ...

Biomarin Pharmaceutical Inc - Richard a. Meier to Retire From Board After Annual Meeting

THOMSON REUTERS
·
Apr 22

Press Release: BioMarin Announces Board Leadership Transition

Dow Jones
·
Apr 22

Is It Time To Reassess BioMarin Pharmaceutical (BMRN) After A 42.7% Three-Year Share Price Fall

Simply Wall St.
·
Apr 10

RBC Capital Sticks to Their Hold Rating for BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Apr 09

BioMarin Pharmaceutical Secures European Regulatory Approval for Amicus Therapeutics Acquisition

MT Newswires Live
·
Apr 07

What BioMarin Pharmaceutical (BMRN)'s Voxzogo Trial Stops and Mixed Safety Data Mean For Shareholders

Simply Wall St.
·
Mar 31

Exploring High Growth Tech Stocks In The US Market March 2026

Simply Wall St.
·
Mar 27

Wells Fargo says buy BioMarin shares amid Phase 2 trial discontinuation weakness

TIPRANKS
·
Mar 17

BioMarin halts Phase 2 VOXZOGO dosing and enrollment in Turner syndrome, SHOX-deficiency and ACAN-deficiency trials

Reuters
·
Mar 16

Biomarin: Decision to Discontinue Following Occurrence of Several Slipped Capital Femoral Epiphysis Events in 2 Ongoing Investigator-Sponsored Trials

THOMSON REUTERS
·
Mar 16

Biomarin Pharmaceutical - Phase 2 Canopy Trials of Voxzogo in Noonan Syndrome, Idiopathic Short Stature to Continue - SEC Filing

THOMSON REUTERS
·
Mar 16

BioMarin reports VOXZOGO trial data showing 4.7 cm additional height gain at four years in children with achondroplasia treated before age 2

Reuters
·
Mar 12

BioMarin Pharmaceutical Is Maintained at Buy by B of A Securities

Dow Jones
·
Mar 11

Biomarin Pharmaceutical Inc : Bofa Global Research Cuts Price Objective to $85.00 From $97.00

THOMSON REUTERS
·
Mar 11

BioMarin price target lowered to $85 from $97 at BofA

TIPRANKS
·
Mar 11

U.S. RESEARCH ROUNDUP-Howmet Aerospace, Nike, Oracle

Reuters
·
Mar 11

PALYNZIQ Pediatric Label Expansion Under REMS Might Change The Case For Investing In BioMarin (BMRN)

Simply Wall St.
·
Mar 11

Absci names Ransi Somaratne chief medical officer as Andreas Busch set to retire

Reuters
·
Mar 07

Camp4 Therapeutics FY 2025 research and collaboration revenue rises 436.5% to USD 3.5 million

Reuters
·
Mar 06

BioMarin Pharmaceutical Is Maintained at Overweight by Barclays

Dow Jones
·
Mar 04